Skip to content
OpenCapital
Get started

ANI Pharmaceuticals ANIP Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$41.46M+26.1%
Viatris logo
ViatrisVTRS
$2.08B+12.9%
ALN
Alnylam PharmaceuticalsALNY
$7.61M+29.6%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$6.9M-39.5%
Amgen logo
AmgenAMGN
$2.37B+7.0%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$2.18M+15.5%

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.89B+18.3%
Enterprise value$1.88B+5.8%
P/E20.5×—
P/S2×-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%—
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's other non-current liabilities?
ANI Pharmaceuticals (ANIP) reported other non-current liabilities of $16.45M in Q1 2026.
How has ANI Pharmaceuticals's other non-current liabilities changed year-over-year?
ANI Pharmaceuticals's other non-current liabilities increased by 134.3% year-over-year, from $7.02M to $16.45M.
What is the long-term trend for ANI Pharmaceuticals's other non-current liabilities?
Over 5 years (2020 to 2025), ANI Pharmaceuticals's other non-current liabilities has grown at a -3.4% compound annual growth rate (CAGR), from $14.48M to $12.16M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.